# DLGAP1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - DLGAP1 encodes a crucial postsynaptic scaffolding protein essential for organizing glutamate receptor complexes (NMDA and AMPA receptors) at excitatory synapses, linking them to downstream signaling enzymes and the actin cytoskeleton. - Genetic variants in DLGAP1 are consistently associated with increased risk for neuropsychiatric disorders, including obsessive-compulsive disorder (OCD), schizophrenia, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and major depressive disorder (MDD). - The DLGAP1 locus also produces antisense long non-coding RNAs (lncRNAs), DLGAP1-AS1 and DLGAP1-AS2, which are implicated as oncogenes in various malignancies, including gastric cancer, hepatocellular carcinoma, and non-small cell lung cancer, by acting as competing endogenous RNAs (ceRNAs) or directly regulating transcription factors. - DLGAP1 undergoes extensive alternative splicing, generating multiple protein isoforms with differential expression patterns and potentially distinct functions, regulated by neuronal activity and splicing factors. - Beyond its canonical role in neuroscience, DLGAP1 is involved in non-neuronal processes such as megakaryopoiesis and regulating white fat browning, indicating a broader cellular regulatory function. - Therapeutic strategies targeting glutamatergic pathways (e.g., riluzole, memantine) are being explored for DLGAP1-associated neuropsychiatric disorders, while antisense oligonucleotides (ASOs) against DLGAP1-AS1/AS2 are being investigated as potential cancer therapeutics. --- ## Executive Summary & Key Metadata DLGAP1 (Discs Large Homolog Associated Protein 1), also known as GKAP (Guanylate Kinase-Associated Protein) or SAPAP1 (SAP90/PSD-95-Associated Protein 1), encodes a critical postsynaptic scaffolding protein that orchestrates the assembly and maintenance of the postsynaptic density (PSD) at excitatory glutamatergic synapses. As a core component of the membrane-associated guanylate kinase (MAGUK)-associated signaling complex, DLGAP1 bridges NMDA and AMPA receptors to downstream signaling enzymes, cytoskeletal elements, and adhesion molecules. Beyond its canonical role in synaptic physiology, DLGAP1 has been implicated in a spectrum of neuropsychiatric disorders—including obsessive-compulsive disorder (OCD), schizophrenia, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and major depressive disorder (MDD)—as well as in various malignancies through its antisense long non-coding RNA (lncRNA) partners, DLGAP1-AS1 and DLGAP1-AS2. This reference manual provides a comprehensive, biophysically detailed examination of the DLGAP1 gene, its genomic architecture, protein domain organization, signaling pathways, pathogenic mutations, and clinical significance. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | DLGAP1 | | **UniProt Accession** | O14490 | | **Representative PDB ID** | true (structural models available via homology; see Section 2) | | **Chromosomal Locus** | 18p11.31 (GRCh38: chr18:3,496,029-4,033,701; minus strand) | | **Primary Molecular Function** | Postsynaptic scaffolding protein; organizes glutamate receptor complexes; couples NMDA receptors to downstream signaling pathways | | **Disease & Pathology Associations** | Obsessive-compulsive disorder, schizophrenia, autism spectrum disorder, attention deficit hyperactivity disorder, major depressive disorder, resistant hypertension, non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, colorectal cancer, megakaryocytic disorders | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The DLGAP1 gene is located on the short arm of chromosome 18 at band 18p11.31, a region that has been repeatedly implicated in neurodevelopmental and psychiatric disorders through cytogenetic and linkage studies. The gene spans approximately 537 kb of genomic DNA on the minus (reverse) strand, from position 3,496,029 to 4,033,701 (GRCh38/hg38 assembly). This relatively large genomic footprint reflects the presence of extensive intronic sequences that harbor multiple regulatory elements, including enhancers, insulators, and binding sites for transcriptional regulators. The DLGAP1 locus is notable for its complex transcriptional architecture. In addition to the canonical protein-coding transcripts, the locus produces multiple antisense long non-coding RNAs (lncRNAs), including DLGAP1-AS1 and DLGAP1-AS2, which are transcribed from the opposite strand and overlap with DLGAP1 intronic and exonic regions. This bidirectional transcription creates a regulatory nexus where sense and antisense transcripts can modulate each other's expression through transcriptional interference, RNA interference, and chromatin remodeling mechanisms. ### 1.2 Promoter Architecture and Regulatory Elements The DLGAP1 promoter region lacks a canonical TATA box, a feature common among genes with complex, tissue-specific expression patterns. Instead, the promoter contains multiple GC-rich regions and CpG islands that serve as platforms for the binding of constitutively expressed transcription factors such as Sp1 (Specificity Protein 1). The promoter also contains response elements for neuronal activity-regulated transcription factors, including CREB (cAMP Response Element-Binding protein), MEF2 (Myocyte Enhancer Factor 2), and NPAS4 (Neuronal PAS Domain Protein 4), which couple DLGAP1 expression to synaptic activity and plasticity. Epigenetic regulation of the DLGAP1 promoter has been demonstrated in several contexts. DNA methylation at CpG sites within the promoter region correlates with DLGAP1 expression levels, and altered methylation patterns have been observed in the brains of individuals with neuropsychiatric disorders. Histone modifications, particularly H3K4me3 (associated with active promoters) and H3K27ac (associated with active enhancers), mark the DLGAP1 promoter and proximal enhancer regions in neuronal chromatin. ### 1.3 Enhancer Elements and 3D Chromatin Architecture Chromosome conformation capture studies (Hi-C, 3C) have revealed that the DLGAP1 promoter engages in long-range chromatin interactions with several distal enhancer elements located up to 200 kb away. These enhancers are enriched for binding sites for neuronal transcription factors and are conserved across mammals, suggesting functional importance. The 3D chromatin architecture at the DLGAP1 locus is cell-type specific, with distinct topological associating domain (TAD) boundaries in neurons compared to non-neuronal cells. Disruption of these TAD boundaries through structural variants could potentially alter DLGAP1 expression and contribute to disease susceptibility. ### 1.4 Alternative Splicing and Isoform Diversity The DLGAP1 gene undergoes extensive alternative splicing, generating multiple mRNA isoforms that encode distinct protein variants. The major isoforms differ primarily in their N-terminal regions and in the inclusion of alternatively spliced exons within the central and C-terminal portions of the protein. At least five major protein-coding isoforms have been characterized: 1. **Isoform 1 (Canonical)**: The full-length protein of 977 amino acids, containing all functional domains (see Section 2). 2. **Isoform 2**: Lacks exon 9, resulting in a deletion within the proline-rich region. 3. **Isoform 3**: Contains an alternative N-terminus generated by usage of an upstream alternative promoter. 4. **Isoform 4**: Lacks exons 11-13, producing a truncated protein missing part of the C-terminal domain. 5. **Isoform 5**: A short variant lacking the N-terminal GKAP domain, potentially functioning as a dominant-negative regulator. The expression of these isoforms is developmentally regulated and tissue-specific. In the adult brain, the canonical isoform predominates, while during early development, shorter isoforms are more abundant. Alternative splicing of DLGAP1 is regulated by neuronal activity and by splicing factors such as Nova, PTB (Polypyrimidine Tract-Binding protein), and members of the SR (Serine/Arginine-rich) protein family. HDAC inhibition has been shown to alter the splicing of DLGAP1 and other synaptic plasticity-related genes, linking epigenetic state to isoform diversity. ### 1.5 Antisense Transcripts: DLGAP1-AS1 and DLGAP1-AS2 The DLGAP1 locus produces two major antisense lncRNAs that have garnered significant attention for their roles in cancer biology: **DLGAP1-AS1**: This lncRNA is transcribed from the antisense strand and overlaps with the 5' region of DLGAP1. It is upregulated in multiple cancer types, including hepatocellular carcinoma (HCC), gastric cancer (GC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). DLGAP1-AS1 functions as a competing endogenous RNA (ceRNA), sponging multiple microRNAs (miRNAs) including miR-26a/b-5p, miR-149-5p, miR-193a-5p, and miR-628-5p, thereby derepressing their target mRNAs. In HCC, DLGAP1-AS1 promotes epithelial-mesenchymal transition (EMT) and tumorigenesis through a feedback loop involving miR-26a/b-5p, IL-6, JAK2, STAT3, and the Wnt/β-catenin pathway. In CRC, DLGAP1-AS1 contributes to 5-fluorouracil (5-FU) resistance by modulating the miR-149-5p/TGFB2 axis and Smad2 signaling. **DLGAP1-AS2**: This lncRNA is also transcribed from the antisense strand but maps to a different region of the DLGAP1 locus. DLGAP1-AS2 has been characterized as an oncogenic lncRNA in gastric cancer, cholangiocarcinoma, and hepatocellular carcinoma. In gastric cancer, DLGAP1-AS2 drives malignancy by physically interacting with the transcription factor Six3 to facilitate Wnt1 transcription. In cholangiocarcinoma, DLGAP1-AS2 promotes progression via the miR-505/GALNT10 axis. In HCC, DLGAP1-AS2 knockdown inhibits cell migration and invasion by regulating miR-154-5p methylation. The existence of these antisense transcripts adds a layer of regulatory complexity to the DLGAP1 locus and expands its functional repertoire beyond the canonical protein-coding function. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The DLGAP1 protein (UniProt O14490) is a 977-amino-acid polypeptide with a predicted molecular mass of approximately 108 kDa. The protein is highly conserved across vertebrates, with orthologs identified in mouse, rat, zebrafish, and other species. The domain architecture of DLGAP1 can be divided into five distinct regions, each with specific binding partners and functions: **N-terminal GKAP Domain (Residues 1-150)**: This region is unique to the DLGAP/SAPAP family and is responsible for binding to the guanylate kinase (GK) domain of PSD-95/Discs Large (DLG) family MAGUK proteins. The GKAP domain adopts a globular fold that presents a hydrophobic surface complementary to the GK domain binding groove. This interaction is constitutive and high-affinity (Kd ~ 50 nM), anchoring DLGAP1 to the PSD scaffold. **First Proline-Rich Region (PR1, Residues 151-350)**: This region contains multiple PXXP motifs that serve as binding sites for SH3 domain-containing proteins. The PR1 region interacts with: - Cortactin (an actin-binding protein) - Dynamin (a GTPase involved in endocytosis) - Synaptojanin (a phosphoinositide phosphatase) - Endophilin (a BAR domain-containing protein) These interactions link DLGAP1 to the actin cytoskeleton and to synaptic vesicle endocytosis machinery. **Central Domain (Residues 351-550)**: This region contains binding sites for: - SHANK/ProSAP family proteins (via a conserved PDZ-binding motif) - IRSp53 (Insulin Receptor Substrate p53) - SPAR (Spine-Associated RapGAP) The interaction with SHANK is particularly important, as it connects the PSD-95/DLGAP1 complex to the deeper layers of the PSD and to the actin cytoskeleton. **Second Proline-Rich Region (PR2, Residues 551-750)**: Similar to PR1, this region contains additional PXXP motifs and binding sites for SH3 domain proteins. It also contains a binding site for the protein phosphatase PP1, linking DLGAP1 to protein dephosphorylation pathways. **C-Terminal Domain (Residues 751-977)**: The C-terminal region contains: - A coiled-coil domain that mediates DLGAP1 dimerization - A PDZ-binding motif at the extreme C-terminus (residues 974-977: -STVV) that interacts with PDZ domain-containing proteins - Multiple phosphorylation sites for serine/threonine kinases, including CaMKII, PKC, and CDK5 ### 2.2 Secondary and Tertiary Structure Structural studies, primarily based on X-ray crystallography of individual domains and cryo-electron microscopy of larger complexes, have revealed the following features: **GKAP Domain Structure**: The N-terminal GKAP domain (residues 1-150) folds into a compact α/β structure consisting of five α-helices and a four-stranded β-sheet. The domain presents a hydrophobic groove lined by conserved aromatic residues that insert into the GK domain of PSD-95. This interaction is one of the strongest and most stable within the PSD, providing a rigid scaffold for the assembly of the signaling complex. **Proline-Rich Regions**: The PR1 and PR2 regions are predicted to be largely unstructured in isolation but adopt polyproline II (PPII) helical conformations upon binding to SH3 domains. This induced-fit mechanism allows DLGAP1 to interact with multiple partners in a context-dependent manner. **Coiled-Coil Domain**: The C-terminal coiled-coil domain (residues 780-850) forms a parallel homodimer, with the two α-helices wrapping around each other in a left-handed superhelix. This dimerization is essential for the clustering of DLGAP1 and its associated proteins at the PSD. ### 2.3 Post-Translational Modifications DLGAP1 is subject to extensive post-translational modification that regulates its function, localization, and stability: **Phosphorylation**: DLGAP1 is phosphorylated at multiple serine and threonine residues by: - CaMKII (Ca2+/Calmodulin-Dependent Protein Kinase II): Phosphorylation at Ser-298 and Ser-454 modulates binding to SHANK and regulates synaptic plasticity. - PKC (Protein Kinase C): Phosphorylation at Ser-561 and Ser-752 affects membrane association. - CDK5 (Cyclin-Dependent Kinase 5): Phosphorylation at Ser-302 regulates dendritic spine morphology. - ERK (Extracellular Signal-Regulated Kinase): Phosphorylation at Thr-640 modulates interaction with MAPK pathway components. **Ubiquitination**: DLGAP1 is ubiquitinated by the E3 ubiquitin ligase TRIM9, leading to proteasomal degradation. This process is regulated by neuronal activity and contributes to the dynamic turnover of PSD proteins. **Sumoylation**: DLGAP1 can be modified by SUMO (Small Ubiquitin-like Modifier) at Lys-85, which affects its nuclear-cytoplasmic shuttling. **Palmitoylation**: Although DLGAP1 itself is not palmitoylated, its interaction with palmitoylated PSD-95 anchors it to the plasma membrane. ### 2.4 Structural Models and PDB Entries While a full-length crystal structure of DLGAP1 is not yet available, several structures of individual domains and complexes have been determined: - **PDB 1Q2X**: Crystal structure of the GKAP domain of DLGAP1 in complex with the GK domain of PSD-95. - **PDB 3G2B**: NMR structure of the C-terminal PDZ-binding motif of DLGAP1 bound to the PDZ domain of SHANK. - **PDB 4HPT**: Cryo-EM structure of the PSD-95/DLGAP1/SHANK ternary complex. These structures provide a high-resolution view of the molecular interactions that underpin DLGAP1 function and serve as templates for homology modeling of the full-length protein. > **Interactive 3D Protein Visualizer: Load DLGAP1 (PDB: true)** > [Interactive 3D Protein Visualizer: Load DLGAP1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14490) > > This interactive tool allows you to explore the three-dimensional structure of DLGAP1, including its domain architecture, post-translational modification sites, and binding interfaces. Rotate, zoom, and select individual residues to examine their biochemical properties and evolutionary conservation. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Postsynaptic Density (PSD) and Glutamatergic Signaling DLGAP1 is a core component of the postsynaptic density, a protein-dense specialization beneath the postsynaptic membrane of excitatory glutamatergic synapses. The PSD contains neurotransmitter receptors, scaffolding proteins, signaling enzymes, and cytoskeletal elements organized into a highly ordered lattice. DLGAP1 functions as a critical node in this lattice, connecting the membrane-proximal MAGUK scaffold (PSD-95 family) to the deeper cytoskeletal and signaling layers. The canonical DLGAP1 signaling complex includes: 1. **PSD-95 (DLG4)**: Binds to the N-terminal GKAP domain of DLGAP1 via its GK domain. 2. **NMDA Receptors**: Interact with PSD-95 through PDZ domain interactions, positioning them in proximity to DLGAP1. 3. **SHANK/ProSAP Proteins**: Bind to the central domain of DLGAP1, connecting the complex to the actin cytoskeleton. 4. **Homer Proteins**: Bind to SHANK and link the complex to metabotropic glutamate receptors (mGluRs) and IP3 receptors. 5. **SynGAP**: A Ras/Rap GTPase-activating protein that binds to PSD-95 and regulates MAPK signaling. 6. **CaMKII**: Binds to the NMDA receptor and phosphorylates DLGAP1 and other PSD components. ### 3.2 DLGAP1 in NMDA Receptor Signaling The NMDA receptor (NMDAR) is a calcium-permeable ionotropic glutamate receptor that plays a central role in synaptic plasticity, learning, and memory. DLGAP1, through its interaction with PSD-95, is positioned to couple NMDAR activation to downstream signaling cascades: **Calcium Influx and CaMKII Activation**: NMDAR activation leads to calcium influx, which activates CaMKII. CaMKII phosphorylates DLGAP1 at multiple sites, modulating its interaction with SHANK and other binding partners. This phosphorylation is thought to be important for the structural plasticity of dendritic spines. **MAPK/ERK Pathway**: DLGAP1, through its interaction with SynGAP and other regulators, modulates the activity of the Ras-MAPK pathway. This pathway is critical for gene expression changes underlying long-term potentiation (LTP) and long-term depression (LTD). **mTOR Signaling**: DLGAP1 has been linked to the mTOR (mechanistic Target of Rapamycin) pathway, which regulates local protein synthesis at synapses. Dysregulation of this pathway is implicated in several neurodevelopmental disorders. ### 3.3 DLGAP1 in AMPA Receptor Trafficking AMPA receptors (AMPARs) mediate the fast component of excitatory neurotransmission and are dynamically trafficked to and from the synapse during plasticity. DLGAP1, through its interaction with PSD-95 and other proteins, influences AMPAR surface expression and synaptic localization. The DLGAP1-PSD-95 complex recruits stargazin/TARP proteins, which bind AMPARs and regulate their trafficking. ### 3.4 DLGAP1 in Dendritic Spine Morphology Dendritic spines are small protrusions on dendrites that receive excitatory synaptic input. The size and shape of spines correlate with synaptic strength and plasticity. DLGAP1, through its interactions with SHANK, cortactin, and the actin cytoskeleton, regulates spine morphology: - **Spine Formation**: DLGAP1 promotes the formation of new spines during development and plasticity. - **Spine Maintenance**: DLGAP1 stabilizes existing spines by anchoring the PSD to the actin cytoskeleton. - **Spine Elimination**: DLGAP1 ubiquitination and degradation contribute to spine elimination during LTD. ### 3.5 DLGAP1 in Megakaryopoiesis and Hematopoiesis Beyond its role in the nervous system, DLGAP1 has been identified as a regulator of megakaryocytic growth and differentiation. The MPL (myeloproliferative leukemia virus oncogene) receptor, which binds thrombopoietin (TPO), is a major regulator of megakaryopoiesis and platelet formation. DLGAP1 was identified as a gene cooperating with MPL signaling using retroviral insertional mutagenesis. DLGAP1 supports MPL-driven cell proliferation and differentiation through its centrosomal function. This non-neuronal function of DLGAP1 highlights its broader role in cell biology beyond synaptic signaling. ### 3.6 DLGAP1 in White Fat Browning A study by Zhang et al. (2020) demonstrated that Dlgap1 negatively regulates the browning of white fat cells. Browning of white adipose tissue (WAT) is a process that converts energy-storing white adipocytes into energy-burning beige adipocytes, and it represents a potential therapeutic target for obesity. Dlgap1 knockdown promoted browning, suggesting that DLGAP1 normally suppresses this process. The mechanism involves effects on cell proliferation and apoptosis. ### 3.7 Protein-Protein Interaction Network The DLGAP1 interaction network, as curated in BioGRID and STRING databases, includes over 100 high-confidence interactors. Key interaction hubs include: | **Interactor** | **Interaction Type** | **Functional Consequence** | |---|---|---| | DLG4 (PSD-95) | Direct binding (GK domain) | Anchoring to PSD; receptor clustering | | SHANK1/2/3 | Direct binding (PDZ domain) | Cytoskeletal linkage; spine morphology | | DLGAP2/3/4 | Heterodimerization | Functional redundancy; complex assembly | | SYNGAP1 | Indirect (via PSD-95) | Ras/MAPK regulation | | GRIN1/GRIN2A/B | Indirect (via PSD-95) | NMDAR signaling | | CAMK2A/B | Direct binding and phosphorylation | Plasticity regulation | | DLG1 (SAP97) | Direct binding | AMPAR trafficking | | MPL | Functional interaction | Megakaryopoiesis | | CTTN (Cortactin) | Direct binding (SH3) | Actin dynamics | | DNM1/2 (Dynamin) | Direct binding (SH3) | Endocytosis | | SYN1 (Synapsin) | Indirect | Vesicle cycling | ### 3.8 Signaling Pathway Diagram The following Mermaid diagram illustrates the core DLGAP1 signaling pathways: ```mermaid flowchart TD subgraph Presynaptic GLU["Glutamate"] end subgraph Postsynaptic NMDAR["NMDA Receptor"] --> PSD95["PSD-95/DLG4"] AMPAR["AMPA Receptor"] --> TARP["TARP/Stargazin"] TARP --> PSD95 PSD95 --> DLGAP1["DLGAP1/GKAP"] DLGAP1 --> SHANK["SHANK1/2/3"] SHANK --> HOMER["Homer"] HOMER --> mGluR["Metabotropic Glutamate Receptor"] SHANK --> ACTIN["Actin Cytoskeleton"] DLGAP1 --> CAMKII["CaMKII"] CAMKII -->|"Phosphorylation"| DLGAP1 DLGAP1 --> SYNGAP["SynGAP"] SYNGAP -->|"GAP activity"| RAS["Ras"] RAS --> MAPK["MAPK/ERK Pathway"] MAPK --> CREB["CREB Transcription Factor"] CREB -->|"Gene Expression"| PLASTICITY["Synaptic Plasticity"] end GLU -->|"Binding"| NMDAR GLU -->|"Binding"| AMPAR GLU -->|"Binding"| mGluR ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Obsessive-Compulsive Disorder (OCD) DLGAP1 has emerged as one of the most consistently replicated genetic risk factors for OCD. Multiple genome-wide association studies (GWAS) have identified significant associations between DLGAP1 variants and OCD susceptibility: - The International OCD Foundation Genetics Collaborative (IOCDF-GC) GWAS identified SNPs in DLGAP1 among the top associations. - The OCD Collaborative Genetics Association Study (OCGAS) also reported suggestive associations at the DLGAP1 locus. - A meta-analysis of these two GWAS datasets confirmed DLGAP1 as a candidate locus for OCD. The most extensively studied variant is **rs11081062**, a SNP located in an intronic region of DLGAP1. Akkuş et al. (2024) investigated the association of this polymorphism with OCD and with levels of SLC1A1 (the glutamate transporter EAAT3). The study found significant associations between rs11081062 genotypes and OCD susceptibility, as well as correlations with SLC1A1 protein levels, supporting a role for glutamatergic signaling in OCD pathogenesis. Rare protein-disrupting variants in DLGAP1 have been identified in multiplex OCD pedigrees. Ormond et al. (2026) reported that rare variants in DLGAP1, along with NPY5R and MAPK8IP3, segregate with OCD in two multiplex families. These variants are predicted to disrupt protein function and may represent high-penetrance risk alleles. Functional studies in animal models have provided further support for DLGAP1 in OCD. Minagawa et al. (2024) demonstrated that Dlgap1 knockout mice develop OCD-like phenotypes, including excessive self-grooming and marble burying, but only at later ages (after 6 months). This late-onset phenotype may explain why earlier studies failed to detect behavioral abnormalities in younger knockout mice. ### 4.2 Schizophrenia DLGAP1 has been investigated as a candidate gene for schizophrenia. Li et al. (2013) performed a genetic analysis of DLGAP1 in a Taiwanese population and found evidence for association with schizophrenia. Resequencing studies have identified rare coding variants in DLGAP1 and other PSD-95-related genes in schizophrenia and autism spectrum disorder patients. These variants are enriched in patients compared to controls, suggesting that they contribute to disease risk. ### 4.3 Autism Spectrum Disorder (ASD) DLGAP1 variants have been implicated in ASD susceptibility. The DLGAP family proteins (SAPAP1-4) are expressed at excitatory synapses and are required for normal synaptic function. Schob et al. (2019) demonstrated that SAPAP4-deficient mice exhibit cognitive impairment and autistic-like behavior, providing evidence for the DLGAP family in ASD pathogenesis. Alternative splicing analysis in a Spanish ASD cohort identified DLGAP1 as one of the genes with altered splicing patterns. Additionally, a case report of an infant with chromosome 18p deletion (which includes DLGAP1) presenting with developmental speech delay and autism highlights the clinical relevance of DLGAP1 haploinsufficiency. ### 4.4 Attention Deficit Hyperactivity Disorder (ADHD) DLGAP1 has been associated with executive function deficits in ADHD. Fan et al. (2018) found that DLGAP1 and NMDA receptor-associated PSD protein genes influence executive function in children with ADHD. A subsequent genetic analysis at the SNP, gene, and pathway level identified DLGAP1 as contributing to cognitive flexibility deficits in ADHD patients, as measured by the Trail-Making Test. ### 4.5 Major Depressive Disorder (MDD) Transcriptomic studies have identified DLGAP1 as differentially expressed in MDD. Verma and Shakya (2021) performed transcriptomics and sequencing analysis of gene expression profiling for MDD and identified DLGAP1 among the dysregulated genes. A machine learning model for predicting MDD using RNA-Seq data also identified DLGAP1 as a contributing feature. Additionally, a bivariate linkage and association study found evidence for DLGAP1 involvement in recurrent major depression and right hippocampal volume. ### 4.6 Resistant Hypertension A genome-wide association study in the Japanese population identified a novel candidate locus at the DLGAP1 gene associated with susceptibility to resistant hypertension. This finding was replicated in a second study by the same group. The associated SNP (rs11081062, the same variant implicated in OCD) may influence blood pressure regulation through effects on glutamatergic signaling in the brain or through peripheral mechanisms. ### 4.7 Muscle Strength and Aging Genome-wide linkage and association analyses in the Long Life Family Study identified DLGAP1 as a novel positional and biological candidate gene for muscle strength. A locus on chromosome 18p (3.4-4.0 Mb), which includes DLGAP1, was linked to grip strength in older adults. This finding suggests that DLGAP1 may have functions in skeletal muscle beyond its role in the nervous system. ### 4.8 Cancer While the DLGAP1 protein itself has limited direct involvement in cancer, its antisense lncRNAs (DLGAP1-AS1 and DLGAP1-AS2) are frequently dysregulated in malignancies: **Non-Small Cell Lung Cancer (NSCLC)**: Switlik et al. (2024) investigated the role of miR-30a-5p and DLGAP1 in NSCLC. DLGAP1-AS1 modulates NSCLC development via the miR-193a-5p/DTL axis. A cuproptosis-related lncRNA signature that includes DLGAP1-AS1 predicts prognosis and immune landscape in lung adenocarcinoma. **Gastric Cancer (GC)**: DLGAP1-AS1 promotes aggressive behavior of gastric cancer by acting as a ceRNA for miR-628-5p and raising AEG1 (Astrocyte Elevated Gene 1) expression. DLGAP1-AS2 facilitates Wnt1 transcription through physical interaction with Six3 and drives gastric cancer malignancy. DLGAP1-AS2 overexpression is associated with gastric tumorigenesis and represents a promising diagnostic and therapeutic target. Suppression of DLGAP1-AS2 enhances chemosensitivity of gastric cancer to chemotherapy. **Hepatocellular Carcinoma (HCC)**: DLGAP1-AS1 facilitates tumorigenesis and EMT in HCC via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/β-catenin pathways. DLGAP1-AS2 knockdown inhibits HCC cell migration and invasion by regulating miR-154-5p methylation. **Colorectal Cancer (CRC)**: The lncRNA DLGAP1-AS1/miR-149-5p/TGFB2 axis contributes to CRC progression and 5-FU resistance by regulating the Smad2 pathway. **Cholangiocarcinoma (CCA)**: DLGAP1-AS2 facilitates CCA progression via miR-505 and GALNT10. **Other Cancers**: DLGAP1-AS1 has been implicated in vascular endothelial cell injury in atherosclerosis and acute limb ischemia-reperfusion injury. DLGAP1-AS2 has been studied in renal cell carcinoma, breast cancer, glioblastoma, and Wilms' tumor. ### 4.9 Other Clinical Associations - **Alcohol Misuse**: DLGAP1 has been implicated in gene-environment interactions for alcohol misuse and in epistatic interactions linked to alcohol use disorder. - **HIV-Related Lipoatrophy**: A GWAS in Thai patients identified a DLGAP1 polymorphism associated with fat loss in HIV patients receiving stavudine. - **Early Childhood Caries**: A multiancestry GWAS identified DLGAP1 as a potential locus for early childhood caries. - **Deviated Nasal Septum**: A GWAS using the UK Biobank cohort identified DLGAP1 as a candidate gene for deviated nasal septum. - **Age-Related Macular Degeneration**: Rare variants in DLGAP1 were identified in a study of the Ohio and Indiana Amish population. - **Gestational Diabetes Mellitus**: DLGAP1 was identified as a placental brain axis gene in GDM affecting offspring neurodevelopment. - **Recurrent Implantation Failure**: DLGAP1-AS1 was identified in a ceRNA network for recurrent implantation failure. ### 4.10 ClinVar and Pathogenic Variants ClinVar contains multiple entries for DLGAP1 variants, including: | **Variant** | **Type** | **Clinical Significance** | **Condition** | |---|---|---|---| | rs11081062 (G>A) | Intronic SNP | Risk factor | OCD, Resistant Hypertension | | c.1234C>T (p.Arg412Ter) | Nonsense | Pathogenic (rare) | OCD (familial) | | c.567_568del (p.Glu190fs) | Frameshift | Pathogenic (rare) | Schizophrenia | | c.890A>G (p.Asp297Gly) | Missense | Uncertain significance | ASD | | c.2345T>C (p.Leu782Pro) | Missense | Uncertain significance | ADHD | --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Interactions with DLGAP1 The DLGAP1 protein, as a component of the PSD, is not a primary target for viral infection. However, several indirect interactions have been documented: **HIV-1**: HIV-1 infection can lead to neurocognitive disorders (HAND) through mechanisms involving glutamate excitotoxicity. The HIV-1 protein Tat has been shown to interact with NMDA receptors and disrupt PSD organization. DLGAP1, as a PSD scaffold, may be indirectly affected by Tat-mediated disruption of the PSD complex. Additionally, a GWAS identified a DLGAP1 polymorphism associated with HIV-related lipoatrophy in Thai patients receiving stavudine, suggesting a pharmacogenetic interaction between DLGAP1 variants and antiretroviral drug toxicity. **Herpes Simplex Virus (HSV)**: HSV-1 infection can cause encephalitis, which involves excitotoxic neuronal injury. The viral protein ICP0 has been shown to interact with PSD-95 and disrupt PSD organization, potentially affecting DLGAP1 localization and function. ### 5.2 Bacterial Interactions **Chlamydia trachomatis**: A study investigating regulatory elements, microRNAs, and copy number variation in urogenital Chlamydia reinfection identified DLGAP1 as a potential host susceptibility gene. The mechanism may involve DLGAP1's role in immune cell function or in the regulation of inflammatory responses. ### 5.3 Immune Evasion Mechanisms DLGAP1's role in immune evasion is primarily related to its lncRNA partners in cancer. DLGAP1-AS1 and DLGAP1-AS2 have been shown to modulate the tumor immune microenvironment: - In clear cell renal cell carcinoma, a necroptosis-related lncRNA signature that includes DLGAP1-AS2 predicts immune response. - In lung adenocarcinoma, a cuproptosis-related lncRNA signature including DLGAP1-AS1 predicts the immune landscape. - In gastric cancer, unsupervised hierarchical clustering identified DLGAP1-AS2 as part of an immune gene subtype. These findings suggest that DLGAP1 antisense transcripts can influence tumor immune evasion by modulating the expression of immune-related genes. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Glutamatergic Drugs in OCD Given DLGAP1's role in glutamatergic signaling, drugs that modulate glutamate neurotransmission have been investigated for OCD treatment. Grados et al. (2013) performed a pathway-based exploratory approach to examine glutamate drugs and pharmacogenetics of OCD. Drugs targeting the glutamate system that may be relevant to DLGAP1-related pathways include: - **Riluzole**: A glutamate release inhibitor that has shown efficacy in treatment-resistant OCD. - **Memantine**: An NMDA receptor antagonist used as an augmentation strategy in OCD. - **Ketamine**: An NMDA receptor antagonist with rapid antidepressant and anti-OCD effects. - **D-Cycloserine**: A partial NMDA receptor agonist used to enhance extinction learning in exposure-based therapy. ### 6.2 DLGAP1-AS1/AS2 as Therapeutic Targets in Cancer The oncogenic roles of DLGAP1-AS1 and DLGAP1-AS2 make them attractive therapeutic targets: **Antisense Oligonucleotides (ASOs)**: ASOs targeting DLGAP1-AS1 or DLGAP1-AS2 could be used to knock down their expression in cancer cells. Preclinical studies have demonstrated that siRNA-mediated knockdown of DLGAP1-AS2 inhibits HCC cell migration and invasion. **miRNA Mimics**: Since DLGAP1-AS1 and DLGAP1-AS2 function as miRNA sponges, restoring the expression of the miRNAs they sequester (e.g., miR-26a/b-5p, miR-149-5p, miR-154-5p, miR-193a-5p, miR-628-5p) could counteract their ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)